Debt ratio at low 14.16%, holding KRW 3.6 billion in cash equivalents and KRW 13.35 billion in short-term financial instruments, no borrowings.
R&D expenses KRW 487 million (up 112% YoY) for continuous investment in new businesses (EV TIM/TRB, LED, cosmetics, contact lens, PFAS replacement, LTO anode).
Litigation risk: civil lawsuit as plaintiff KRW 440 million and criminal lawsuit as defendant (amount uncertain), provision of KRW 689 million recognized.
Subsidiary Aerogel Korea recorded revenue KRW 330 million and net loss KRW 86 million.
No material changes in financial statement notes, no changes in dividend policy.